Sunnie Kim, assistant professor, medicine — medical oncology, University of Colorado Anschutz Medical Campus, contextualizes the use of tislelizumab (BGB-A317) as a frontline treatment option in advanced esophageal squamous cell carcinoma (ESCC).
CU Anschutz
Academic Office One
12631 East 17th Avenue
8601
Aurora, CO 80045